<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317187</url>
  </required_header>
  <id_info>
    <org_study_id>100791</org_study_id>
    <nct_id>NCT00317187</nct_id>
  </id_info>
  <brief_title>Safety Study of a Vaccine Against Meningitis in Infants (2,4 &amp; 6 Months Age) After a Birth Dose of Hepatitis B.</brief_title>
  <official_title>Partially Blinded Study to Assess Reactogenicity &amp; Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ in Healthy Infants After a Hepatitis B Birth Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the reactogenicity &amp; safety of
      Tritanrix™-HepB/Hib-MenAC vaccine to the international standard of care,
      Tritanrix™-HepB/Hiberix™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized study with four groups to receive one of the following vaccination regimens after
      a dose of hepatitis B vaccine given at birth:

        -  One of the 3 lots of GSK Biologicals' Hib-MenAC mixed with GSK Biologicals'
           Tritanrix™-HepB (3 different groups)

        -  GSK Biologicals' Tritanrix™-HepB/Hiberix™
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2004</start_date>
  <completion_date type="Actual">January 16, 2005</completion_date>
  <primary_completion_date type="Actual">January 16, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of fever &gt; 38.5°C(axillary) during the 4-day follow-up period after dose 1</measure>
    <time_frame>Days 0-3 post dose 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of fever &gt; 38.5°C(axillary) during the 4-day follow-up period after dose 2</measure>
    <time_frame>Days 0-3 post dose 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of fever &gt; 38.5°C(axillary) during the 4-day follow-up period after dose 3</measure>
    <time_frame>Days 0-3 post dose 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited symptoms other than fever &gt;38.5°C (axillary) during the 4-day follow-up period after each dose</measure>
    <time_frame>Days 0-3 after each dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited symptoms during the 31-day follow-up period after each dose</measure>
    <time_frame>Day 0-30 after each dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events during the entire study period</measure>
    <time_frame>Day 0 up to Month 5</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Diphtheria</condition>
  <condition>Whole Cell Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <arm_group>
    <arm_group_label>Hib-MenAC Lot 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hib-MenAC Lot 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hib-MenAC Lot 3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hiberix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tritanrix-HepB/Meningitec conjugate vaccine</intervention_name>
    <description>The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection</description>
    <arm_group_label>Hib-MenAC Lot 1 Group</arm_group_label>
    <arm_group_label>Hib-MenAC Lot 2 Group</arm_group_label>
    <arm_group_label>Hib-MenAC Lot 3 Group</arm_group_label>
    <other_name>DTPw-HBV/Hib-MenAC conjugate vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tritanrix/Hiberix vaccine</intervention_name>
    <description>The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.</description>
    <arm_group_label>Hiberix Group</arm_group_label>
    <other_name>DTPw-HBV/Hib vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        • Healthy infants 56-83 days of age at the time of the first vaccine dose, written informed
        consent obtained from the parents, born after a gestation period of 36 to 42 weeks &amp; has
        received a birth dose of hepatitis B vaccine within the first 3 days of life.

        Exclusion criteria:

          -  Any confirmed immunodeficient condition, based on medical history and physical
             examination.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before the first dose of study vaccine, or planned administration
             during the study period with the exception of oral polio vaccine (OPV).

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use
             during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs since birth.

          -  Bacille Calmette-Guérin (BCG) vaccine received after the first 2 weeks of life.

          -  Previous vaccination against diphtheria, tetanus, pertussis, Haemophilus influenzae
             type b, and/or meningococcal disease.

          -  History of diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b
             and/or meningococcal disease or known exposure to these diseases since birth.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>56 Days</minimum_age>
    <maximum_age>83 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 17, 2006</study_first_submitted>
  <study_first_submitted_qc>April 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2006</study_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

